AnaptysBio Completes Royalty-Only Pivot With CEO, CFO on Consulting Contracts
Company Background
AnaptysBio (Nasdaq: ANAB), roughly $1.6 billion in market cap, spent more than a decade as a clinical-stage immunology company before deciding in late 2025 to split itself in two. The biopharma operations — including rosnilimab, ANB033 and ANB101 — were spun out as First Tracks Biotherapeutics (Nasdaq: TRAX) on April 20, 2026. What remained is a royalty management shell whose entire value rests on two out-licensed antibodies: dostarlimab (Jemperli), sold by GSK, and imsidolimab, licensed to Vanda Pharmaceuticals.
Jemperli is the dominant asset. Royalty rates run from 8% on net sales below $1 billion up to 25% above $2.5 billion, with GSK guiding to peak monotherapy sales of more than £2 billion ($2.7 billion). Management has projected that peak annualized royalties payable to AnaptysBio could exceed $390 million. Against that income stream sits a non-recourse royalty monetization with Sagard Healthcare Partners, carrying a remaining balance of roughly $325 million as of May 2026, with paydown expected by the end of Q2 2027.
The complication is litigation. In November 2025, AnaptysBio sued Tesaro (a GSK subsidiary) and GSK in Delaware Chancery Court, alleging Tesaro materially breached the Collaboration Agreement by running clinical trials that benefit competitor PD-1s and failing to seek the optimum commercial return for Jemperli. GSK and Tesaro filed their own counter-complaint the same day. AnaptysBio's complaint asks the court to declare Tesaro's breaches incurable and to revert all dostarlimab rights back to AnaptysBio — a remedy that would be existentially disruptive to GSK's oncology franchise if granted.
What Was Disclosed
On May 18, 2026, the Board of Directors approved a change in AnaptysBio's fiscal year-end from December 31 to June 30. The company will file a transition report on Form 10-KT for the six-month period from January 1, 2026 through June 30, 2026, then shift to quarterly reporting on the new calendar beginning with the quarter ending September 30, 2026. The filing offers no stated rationale for the change. That same week, a separate 8-K filed May 11, 2026 disclosed the appointment of Christopher Murphy as Chief Financial Officer — on a consulting agreement rather than as a full employee — and the appointment of Owen Hughes, currently CEO of XOMA Royalty, to the Board.
Why It Matters
AnaptysBio has restructured itself to a degree that few public companies attempt: both its president and CEO (Daniel Faga) and its new CFO (Christopher Murphy) are engaged as independent contractors, not employees. Faga's consulting agreement runs at least through January 15, 2027; Murphy's carries monthly fees of $42,916.66 with no base salary. The two new board directors — Susannah Gray, former CFO of Royalty Pharma, and Owen Hughes of XOMA Royalty — bring explicit royalty-management credentials, signaling that the board intends to run the company as a pure monetization vehicle. The fiscal year shift to a June 30 close neatly packages the stub period covering the spin-off and creates a clean reporting cadence going forward.
The operating model is lean almost by necessity. Management has guided to an EBIT margin above 95%, which is achievable only because nearly all expenses transferred to First Tracks along with the employees. But Q1 2026 general and administrative costs nearly doubled year-over-year to $26.2 million, driven by separation expenses and, notably, ongoing legal costs from the GSK litigation — a cost line that will not disappear. The litigation itself is the central risk: AnaptysBio's complaint alleges that Tesaro and GSK have been running clinical trials pairing GSK's antibody-drug conjugates with competitor PD-1s rather than Jemperli, structurally undermining dostarlimab's commercial return. AnaptysBio is seeking a court declaration that Tesaro's breaches are incurable and that dostarlimab rights revert to AnaptysBio — a nuclear outcome for both sides.
The countervailing facts are real. Jemperli reported $313 million in Q1 2026 sales with greater than 40% year-over-year growth, according to GSK's earnings. A U.S. FDA PDUFA date of December 12, 2026 for imsidolimab in generalized pustular psoriasis adds a nearer-term milestone catalyst. And the Sagard paydown trajectory means AnaptysBio could be receiving royalties unencumbered by the monetization liability as early as mid-2027. The restructuring, however novel its form, is calibrated to extract maximum cash from these two collaborations — as long as the courts do not hand AnaptysBio a Pyrrhic victory by awarding it back an asset it would then have no infrastructure to commercialize.